Taiko Pharma Expands Operations In China
This article was originally published in PharmAsia News
Taiko Pharma stock continues to rise, showing a favorable outlook for their main product in China, Sugar-Coated Seirogan A and for regional expansion.
You may also be interested in...
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.